浙江医药股份有限公司 第九届十六次董事会审议的 内控制度汇编 二〇二三年十二月 | 股东大会议事规则 | | 2 | | --- | --- | --- | | 累积投票制实施细则 | | 12 | | 董事会议事规则 | | 15 | | 独立董事制度 | | 24 | | 关联交易决策规则 | | 34 | | 董事会战略委员会工作细则 | | 42 | | --- | --- | --- | | 董事会提名委员会工作细则 | | 45 | | 董事会审计委员会工作细则 | | 49 | | 董事会薪酬与考核委员会工作细则 | | 52 | 股东大会议事规则 第一章 总 则 第一条 为规范浙江医药股份有限公司(以下简称公司)行为，保证股东大会依法 行使职权，根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共和 国证券法》（以下简称《证券法》）、《上市公司股东大会规则》《上市公司治理准则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》和《浙江医药股份有限公 司章程》(以下简称《公司章程》)的规定，特制定本议事规则。 第二条 公司应严格按照法律、行政法规、《公司章程》及本规则的相 ...

根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江医药股份有限公司（以下简称"公司"）收到国家药品监督管 理局核准签发关于SH-337片的《药物临床试验批准通知书》，经审查，SH-337 片临床试验申请符合药品注册的有关要求，同意本品开展临床试验。现将相关 情况公告如下： 一、药品基本情况 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 2023年09月12日受理的SH-337片临床试验申请符合药品注册的有关要求，同意本 品开展临床试验。 二、药品研究及相关情况 SH-337 片拟用于消化系统酸相关性疾病的治疗。根据 PDB 药物综合数据库， 其同类药物富马酸伏诺拉生片 2022 年全球销售额 8.87 亿美元。米内数据查询， 武田制药的富马酸伏诺拉生片 2022 年国内销售额 5.01 亿元人民币。截至目前， 公司用于开展 SH-337 片项目已累计投入研发费用 3901 万元。 三、风险提示 证券代码：600216 证券简称 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥1,938,575,549.72, representing a decrease of 3.37% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥29,077,469.36, down 69.02% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥19,866,763.83, a decrease of 65.40% compared to the same period last year[5]. - The basic earnings per share for Q3 2023 was ¥0.03, reflecting a decline of 70.00% year-on-year[8]. - The diluted earnings per share for Q3 2023 was also ¥0.03, down 70.00% compared to the previous year[8]. - Total operating revenue for the first three quarters of 2023 was ¥5,876,518,447.27, a decrease of 4.03% from ¥6,123,873,142.30 in the same period of 2022[25]. - Net profit for the third quarter of 2023 was ¥180,865,708.32, down 49.5% from ¥357,899,312.31 in the third quarter of 2022[31]. - Earnings per share (EPS) for the third quarter of 2023 was ¥0.31, compared to ¥0.51 in the same quarter of 2022, indicating a decline of 39.22%[34]. - The total comprehensive income for the third quarter of 2023 was ¥186,624,795.41, down from ¥356,603,152.85 in the third quarter of 2022[34]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥12,592,865,822.47, an increase of 1.29% from the end of the previous year[8]. - The company's current assets totaled RMB 5,496,405,372.79, down from RMB 5,654,960,631.32 at the end of 2022, indicating a decrease of about 2.79%[21]. - The company's non-current assets totaled RMB 7,096,460,449.68, an increase from RMB 6,777,655,573.75, indicating a growth of about 4.71%[23]. - Total current liabilities amounted to RMB 2,572,418,753.41, up from RMB 2,465,364,489.37, reflecting an increase of about 4.34%[23]. - The total liabilities of the company increased, indicating a potential need for strategic financial management moving forward[23]. - The total liabilities decreased slightly to ¥2,693,536,016.72 in 2023 from ¥2,722,757,157.71 in 2022[25]. - The total equity attributable to shareholders increased to ¥9,513,444,658.10 in 2023 from ¥9,259,881,857.33 in 2022, representing a growth of 2.74%[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥410,703,114.95, showing a significant increase of 190.83%[8]. - In the first three quarters of 2023, the cash inflow from operating activities totaled ¥6,332,953,973.34, a decrease of 1.21% compared to ¥6,410,825,337.82 in the same period of 2022[35]. - The net cash flow from operating activities for the first three quarters of 2023 was ¥410,703,114.95, significantly up from ¥141,215,952.32 in 2022, marking an increase of 190.0%[39]. - The total cash outflow from operating activities was ¥5,922,250,858.39, down 5.53% from ¥6,269,609,385.50 in the previous year[39]. - The cash inflow from investment activities was ¥1,073,692,177.04, an increase of 21.6% compared to ¥882,538,505.81 in 2022[39]. - The net cash flow from investment activities was -¥379,469,679.41, an improvement from -¥708,767,925.08 in the same period last year[39]. - The cash inflow from financing activities was ¥455,055,038.00, a decrease of 59.0% from ¥1,112,094,793.67 in 2022[39]. - The net cash flow from financing activities was -¥133,635,239.73, compared to a positive net cash flow of ¥88,355,749.67 in the previous year[39]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2023 was ¥1,349,552,417.87, slightly up from ¥1,304,784,270.68 in 2022[41]. Shareholder Information - The company reported a total of 68,414 common shareholders at the end of the reporting period[13]. - The major shareholder, New Changxing Investment Development Co., Ltd., holds 21.65% of the shares, totaling 208,192,361 shares[13]. Operational Costs and Expenses - Total operating costs increased to ¥5,607,285,954.16 in 2023 from ¥5,498,607,942.85 in 2022, reflecting a rise of 1.58%[28]. - Research and development expenses rose to ¥607,134,841.28 in 2023, up from ¥555,393,836.63 in 2022, marking an increase of 9.31%[28]. - The company reported a financial expense of -¥20,691,217.89 in 2023, an improvement compared to -¥37,178,071.08 in 2022[28]. - The company reported a decrease in cash received from sales of goods and services, totaling ¥5,934,987,440.73, down from ¥5,971,286,493.18 in the previous year[35]. - The company’s cash outflow for employee compensation increased to ¥758,372,339.25, up from ¥691,421,649.18 in the same period last year, reflecting a rise of 9.7%[39]. Other Comprehensive Income - Other comprehensive income after tax for the third quarter of 2023 was ¥5,759,087.09, compared to -¥1,296,159.46 in the same quarter of 2022[31].

证券代码：600216 证券简称：浙江医药 公告编号：2023-032 浙江医药股份有限公司 关于子公司收到化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）控股子公司浙江昌海制药有限 公司（以下简称"昌海制药"）于 2023 年 10 月 19 日收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的达托霉素《化学原料药上市申请批准通知书》 （通知书编号：2023YS00704）。现将相关情况公告如下： 一、药品的基本情况 化学原料药名称：达托霉素 注册标准编号：YBY68262023 2023 年 6 月 29 日，昌海制药达托霉素原料药生产线通过了美国食品药品监 督管理局的 cGMP（现行药品生产质量管理规范）现场检查（详见公司于 2023 年 7 月 1 日在上海证券交易所网站披露的 2023-025 号公告）。 三、对上市公司的影响及风险提示 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定 ...

2023 年 9 月 28 日，邵旻之先生取得上海证券交易所董事会秘书任职培训证 明，邵旻之先生自取得该证明之日起正式履行董事会秘书职责。 特此公告。 证券代码：600216 证券简称：浙江医药 公告编号：2023-031 浙江医药股份有限公司关于董事会秘书履职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）于 2023 年 6 月 6 日下午在浙江 医药总部 1 号楼 401 会议室召开了第九届十三次董事会会议，审议通过了《关于 改聘第九届董事会董事会秘书的议案》，聘任邵旻之先生担任董事会秘书，具体 详见公司 2023 年 6 月 8 日在上海证券交易所网站（www.sse.com.cn）发布的《浙 江医药关于改聘董事会秘书的公告》（公告编号：2023-022）。 1 浙江医药股份有限公司董事会 2023 年 10 月 12 日 ...

证券代码：600216 证券简称：浙江医药 公告编号：2023-030 浙江医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江医药股份有限公司下属子公司浙江新码生物医药有限公司（以下 简称"公司"）收到国家药品监督管理局下发的关于公司在研药物注射用NCB003 的《药物临床试验批准通知书》，同意本品单药在晚期实体瘤开展临床试验。现 将相关情况公告如下： 一、药品基本情况 1、药物名称：注射用NCB003 2、剂型：注射剂 3、规格：1 mg/瓶 二、药品研究情况 注射用NCB003是公司自主研发的新一代定点偶联长效人白介素-2药物，拟 用于标准治疗失败的晚期恶性实体瘤，属于创新生物技术药物。 截至 2023 年 8 月，公司 NCB003 项目已累计投入研发费用 6283.21 万元人 民币（未经审计）。 三、药品的其他相关情况 白介素-2具有显著的增强免疫作用和很好的抗肿瘤临床应用潜力，国内外有 多种重组人白介素-2上市产品应用于癌症治疗。但是白介素-2在 ...

证券代码：600216 证券简称：浙江医药 公告编号：2023-029 浙江医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日(星期四)15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心视频直播和网络互动 三、参加人员 公司副董事长、总裁吕春雷先生，独立董事裘益政先生，董事会秘书叶伟 东先生，财务总监李齐融女士。 投资者可于 2023 年 09 月 07 日(星期四)至 09 月 13 日(星期三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@zmc-china.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进 ...

Financial Performance - The company reported a total revenue of 33,311,713.89 RMB for the first half of 2023, with a significant contribution from non-operating income [36]. - The company's revenue for the first half of 2023 was approximately ¥3.94 billion, a decrease of 4.36% compared to the same period last year [45]. - Net profit attributable to shareholders decreased by 30.29% to approximately ¥272.26 million compared to the previous year [45]. - The net cash flow from operating activities was approximately ¥252.46 million, a significant improvement from a negative cash flow of ¥8.31 million in the same period last year [45]. - The basic earnings per share decreased by 31.71% to ¥0.28 compared to ¥0.41 in the previous year [45]. - The weighted average return on equity decreased by 1.52 percentage points to 2.88% compared to the same period last year [45]. - The company's total assets increased by 2.32% to approximately ¥12.72 billion compared to the end of the previous year [45]. - The net assets attributable to shareholders increased by 4.21% to approximately ¥9.65 billion compared to the end of the previous year [45]. - The company reported a net profit margin of 12%, reflecting improved operational efficiency [153]. Operational Highlights - The company experienced a non-operating loss from the disposal of non-current assets totaling -5,449,085.81 RMB [16]. - The company has not faced any significant operational risks during the reporting period [23]. - The company’s main business remains unchanged, focusing on life nutrition products, pharmaceutical manufacturing, and pharmaceutical commerce [37]. - The pharmaceutical commerce segment primarily involves the distribution of tendered drugs, with retail as a supplementary service [38]. - The company continues to focus on the production of life nutrition products and pharmaceutical manufacturing, including various vitamins and pharmaceutical raw materials [49]. - The company is expanding its sales of animal nutrition products primarily through self-export to Europe and the United States, as well as through domestic and international trade companies [53]. - The company has established business relationships with large dietary supplement manufacturers and major cosmetic companies for human nutrition products [53]. Financial Management - The company has established a supplier evaluation system to ensure the quality of raw materials, complying with FDA and TGA standards [38]. - The company recognizes unconditional rights to receive consideration from customers as receivables, while rights to receive consideration that depend on factors other than the passage of time are recognized as contract assets [82]. - The company applies a simplified measurement method for expected credit losses on receivables and contract assets [102]. - Long-term equity investments formed through multiple transactions are accounted for separately in individual and consolidated financial statements [85]. - The company capitalizes borrowing costs directly attributable to the acquisition or production of qualifying assets, while other borrowing costs are recognized as expenses in the current period [120]. - The company assesses impairment for long-term assets, including goodwill and intangible assets with indefinite useful lives, annually regardless of impairment indicators [125]. - The depreciation method for fixed assets is based on the straight-line method, with useful lives ranging from 5 to 40 years depending on the asset type [118]. - The company recognizes biological assets when they meet specific criteria, including reliable measurement of costs and expected economic benefits [122]. - The company has established methods for recognizing contract liabilities [126]. - The company does not apply the expected credit loss determination methods for other debt investments [83]. - The company has not applied the expected credit loss determination methods for long-term receivables [84]. Future Outlook and Strategy - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 10% to $1.65 billion [153]. - New product launches are expected to contribute an additional $200 million in revenue over the next fiscal year [153]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience [153]. - Market expansion plans include entering three new international markets by Q4 2023, targeting a 5% increase in global market share [153]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $100 million allocated for potential deals [153]. - A new marketing strategy is set to increase brand awareness, aiming for a 30% growth in customer engagement metrics [153]. Certification and Compliance - The company obtained the High-tech Enterprise Certificate, allowing a 15% corporate income tax rate from 2020 to 2022 [166]. - The company has received a High-tech Enterprise Certificate valid from January 1, 2021, to December 31, 2023, allowing a 15% corporate income tax rate [167]. - The company has undergone a review and received a High-tech Enterprise Certificate valid from January 1, 2022, to December 31, 2024, with a 15% corporate income tax rate [188]. Cash and Liquidity - Cash and cash equivalents stood at $300 million, providing a strong liquidity position for future investments [153]. - The company reported a total cash balance of CNY 1,507,694,005.84 at the end of the period, an increase from CNY 1,438,077,266.91 at the beginning of the period [191]. - The company has a total of CNY 1,320,098,350.67 in accounts receivable, with CNY 1,306,397,953.15 due within one year [194]. - The company has a total of CNY 258,187,425.95 in bank acceptance bills that are endorsed or discounted but not yet due [181]. - The company reported cash and cash equivalents of CNY 108,384.54 at the end of the period, up from CNY 83,589.76 at the beginning [191]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months [184]. Governance and Reporting - The company’s financial report has been confirmed by the board of directors for its authenticity and completeness [20]. - The company’s stock is listed on the Shanghai Stock Exchange under the code 600216 [32]. - The company’s office and registered address remain unchanged at 168 Zhiyuan Middle Avenue, Binhai New City, Shaoxing, Zhejiang [31]. - The company has specific accounting policies for financial instruments impairment, fixed asset depreciation, and income recognition [185]. - The company has not made any significant changes to its accounting policies or estimates during the reporting period [187].

证券代码：600216 证券简称：浙江医药 公告编号：2023-027 浙江医药股份有限公司关于下属生产企业新昌制药厂通过 韩国 MFDS 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）下属生产企业新昌制药厂（以 下简称"新昌制药"）于 2023 年 05 月 30 日-06 月 01 日接受了来自韩国食品药 品管理局（以下简称"MFDS"）的 cGMP（现行药品生产质量管理规范）现场检 查，检查内容为盐酸万古霉素原料药日常监督检查。 2023 年 8 月 21 日，新昌制药收到 MFDS 的通知函和针对本次检查签发的现 场检查报告，确认本次检查已结束，检查结果为通过。该通知说明新昌制药的质 量管理体系符合韩国 MFDS 的标准，顺利通过了本次韩国 MFDS 的日常监督检查。 现将相关信息公告如下： 一、MFDS 现场检查的相关信息 1、企业名称：浙江医药股份有限公司新昌制药厂 4、检查范围：盐酸万古霉素 二、生产车间及生产品种 通过本次韩国 MFDS 现场检查的 ...

证券代码：600216 证券简称：浙江医药 公告编号：2023-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 09 日(星期二)至 05 月 15 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@zmc- china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江医药股份有限公司（以下简称"公司"）已于 2023 年 04 月 26 日发布公 司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成 果、财务状况，公司计划于 2023 年 05 月 16 日上午 10:00-11:00 举行 2022 年度 业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、 说 ...